OCUL Analyst Estimates: Price Targets, Revenue, Net Income, and EBIT Forecast - Ocular Therapeutix Inc - Alpha Spread

First Time Loading...

Watchlist Manager

Watchlist

Price: 4.74 USD -1.25%

Updated:

Section:

Wall Street
Price Targets

Wall Street analysts forecast OCUL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for OCUL is 15.81 USD with a low forecast of 11.11 USD and a high forecast of 25.2 USD.

OCUL Lowest Forecast

Wall Street Target

OCUL Average Forecast

Wall Street Target

OCUL Highest Forecast

Wall Street Target

134% Upside

234% Upside

432% Upside

The latest public price target was made on Mar 12, 2024 by Jonathan Wolleben from JMP Securities , who expects OCUL stock to rise by 406% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst	Price Target	Date	Article
Jonathan Wolleben JMP Securities	24 USD Upside 406%	1 month ago Mar 12, 2024	Ocular Therapeutix (OCUL) PT Raised to $24 at JMP Securities StreetInsider

Price Target	24 USD
Upside/Downside	406%

Santen Pharmaceutical Co Ltd

15% Upside

Guobang Pharma Ltd

47% Upside

Inner Mongolia Furui Medical Science Co Ltd

51% Downside

Whanin Pharm Co Ltd

51% Upside

Santen Pharmaceutical Co Ltd

15% Upside

Guobang Pharma Ltd

47% Upside

Inner Mongolia Furui Medical Science Co Ltd

51% Downside

Whanin Pharm Co Ltd

51% Upside

Dong-A Socio Holdings Co Ltd

32% Upside

Sundial Growers Inc

50% Upside

Clearside Biomedical Inc

345% Upside

Recordati Industria Chimica e Farmaceutica SpA

4% Upside

Revenue
Forecast

For the last 8 years the compound annual growth rate for Ocular Therapeutix Inc's revenue is 55%. The projected CAGR for the next 3 years is 20%.

55%

20%

-6%

What are analyst estimates?

Operating Income
Forecast

N/A

N/A

0%

What are analyst estimates?

Net Income
Forecast

N/A

N/A

-74%

What are analyst estimates?

See Also

Relative Valuation

Wall Street Estimates

Profitability Analysis

Solvency Analysis

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

According to Wall Street analysts, the average 1-year price target for OCUL is 15.81 USD with a low forecast of 11.11 USD and a high forecast of 25.2 USD.

For the last 8 years the compound annual growth rate for Ocular Therapeutix Inc's revenue is 55%. The projected CAGR for the next 3 years is 20%.

Join more than 133,000+ value investors using Alpha Spread

Create a free account

or see our plans & pricing

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

What is Intrinsic Value? Help Center Contact Us

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.